Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma
Molecular Cancer Research (2015) - Comment
pubmed: 25421750  doi: 10.1158/1541-7786.mcr-14-0157  issn: 1541-7786  issn: 1557-3125 

M. Ceccon, L. Mologni, G. Giudici, R. Piazza, A. Pirola, D. Fontana, C. Gambacorti-Passerini